<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02097641</url>
  </required_header>
  <id_info>
    <org_study_id>UCSF-hMSC-ARDS-P2</org_study_id>
    <secondary_id>1U01HL108713-01</secondary_id>
    <nct_id>NCT02097641</nct_id>
  </id_info>
  <brief_title>Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome (START)</brief_title>
  <acronym>START</acronym>
  <official_title>Prospective, Randomized, Multi-center Phase 2 Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stem Cells for the Treatment of Acute Respiratory Distress Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael A. Matthay</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center study to assess
      the safety and efficacy of a single dose of Allogeneic Bone Marrow-derived Human Mesenchymal
      Stem Cells infusion in patients with Acute Respiratory Distress Syndrome (ARDS). This study
      is the extension of the Phase 1 pilot study (NCT01775774). Patients will be randomized to
      receive Human Mesenchymal Stem Cells infusion or placebo in a 2:1 allocation. Patients will
      be followed daily for adverse events through day 28, death or hospital discharge, whichever
      occurs first. Vital status will be collected at 6 and 12 months after study enrollment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 15, 2014</start_date>
  <completion_date type="Actual">February 9, 2018</completion_date>
  <primary_completion_date type="Actual">March 9, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of pre-specified infusion associated events occurring within 6 hours of study infusion</measure>
    <time_frame>6 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Any cardiac arrest or death within 24 hours of study infusion</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Any unexpected severe adverse events in two groups</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Respiratory efficacy endpoints which include lung injury score, PaO2/FiO2 ratio and oxygenation index at day 3.</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic efficacy endpoints which include SOFA score, ventilator-free days, organ failure free days, mortality, et al.</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological efficacy endpoints which includes serial levels of plasma and urine biomarkers.</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Respiratory Distress Syndrome, Adult</condition>
  <arm_group>
    <arm_group_label>Human Mesenchymal Stem Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plasma-Lyte A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells</intervention_name>
    <description>Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.</description>
    <arm_group_label>Human Mesenchymal Stem Cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Plasma-Lyte A</intervention_name>
    <description>Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.</description>
    <arm_group_label>Plasma-Lyte A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients will be eligible for inclusion if they meet all of the below criteria. Criteria
        1-3 must all be present within a 24-hour time period and at the time of enrollment:

        Acute onset (defined below) of:

          1. A need for positive pressure ventilation by an endotracheal or tracheal tube with a
             PaO2/FiO2 ratio &lt; 200 with at least 8 cm H2O positive end-expiratory airway pressure
             (PEEP)

          2. Bilateral infiltrates consistent with pulmonary edema on frontal chest radiograph

          3. No clinical evidence of left atrial hypertension for bilateral pulmonary infiltrates.

        Exclusion Criteria:

          1. Age less than 18 years

          2. Greater than 96 hours since first meeting ARDS criteria per the Berlin definition of
             ARDS

          3. Pregnant or breast-feeding

          4. Prisoner

          5. Presence of any active malignancy (other than non-melanoma skin cancer) that required
             treatment within the last 2 years

          6. Any other irreversible disease or condition for which 6-month mortality is estimated
             to be greater than 50%

          7. Moderate to severe liver failure (Childs-Pugh Score &gt; 12)

          8. Severe chronic respiratory disease with a PaCO2 &gt; 50 mm Hg or the use of home oxygen

          9. Patient, surrogate, or physician not committed to full support (exception: a patient
             will not be excluded if he/she would receive all supportive care except for attempts
             at resuscitation from cardiac arrest)

         10. Major trauma in the prior 5 days

         11. Lung transplant patient

         12. No consent/inability to obtain consent

         13. Moribund patient not expected to survive 24 hours

         14. WHO Class III or IV pulmonary hypertension

         15. Documented deep venous thrombosis or pulmonary embolism within past 3 months

         16. No arterial line/no intent to place an arterial line

         17. No intent/unwillingness to follow lung protective ventilation strategy or fluid
             management protocol

         18. Currently receiving extracorporeal life support (ECLS) or high-frequency oscillatory
             ventilation (HFOV)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A Matthay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2014</study_first_submitted>
  <study_first_submitted_qc>March 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2014</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Michael A. Matthay</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Allogeneic Bone Marrow-derived Human Mesenchymal Stem Cells</keyword>
  <keyword>Acute Respiratory Distress Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasma-lyte 148</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

